PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsVelpatasvir
Epclusa(velpatasvir)
Epclusa, Vosevi (velpatasvir) is a small molecule pharmaceutical. Velpatasvir was first approved as Epclusa on 2016-06-28. It is used to treat chronic hepatitis c and hepatitis c in the USA. It has been approved in Europe to treat chronic hepatitis c.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
digestive system diseasesD004066
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Combinations
Epclusa, Vosevi
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Sofosbuvir
+
Velpatasvir
Tradename
Company
Number
Date
Products
EPCLUSAGilead SciencesN-208341 RX2016-06-28
2 products, RLD, RS
EPCLUSAGilead SciencesN-214187 RX2021-06-10
2 products, RLD, RS
Sofosbuvir
+
Velpatasvir
+
Voxilaprevir
Tradename
Company
Number
Date
Products
VOSEVIGilead SciencesN-209195 RX2017-07-18
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
epclusaNew Drug Application2024-06-05
epclusa accessExport only2025-04-24
sofosbuvir and velpatasvirNDA authorized generic2025-03-06
voseviNew Drug Application2025-07-14
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hepatitis c—D006526B19.2
chronic hepatitis cEFO_0004220D019698B18.2
Agency Specific
FDA
EMA
Expiration
Code
SOFOSBUVIR / VELPATASVIR, EPCLUSA, GILEAD SCIENCES INC
2028-12-10PED
2028-06-10ODE-376
2027-09-19PED
2027-03-19ODE-293
2025-04-27M-277
2024-01-14PED
2023-07-14M-264
Patent Expiration
Patent
Expires
Flag
FDA Information
Sofosbuvir / Velpatasvir / Voxilaprevir, Vosevi, Gilead Sciences Inc
109128142037-06-01DP
113380072037-06-01DPU-2039, U-2040
92967822034-07-17DS, DP
98687452032-11-16DS, DP
89570462028-03-21U-2039, U-2040
Sofosbuvir / Velpatasvir, Epclusa, Gilead Sciences Inc
97574062034-01-30DP
100860112034-01-30U-1470
111167832034-01-30DPU-1470, U-2039, U-2040
117074792034-01-30DPU-1470
85751352032-11-16DS, DPU-1470, U-2039, U-2040
89213412032-11-16DS, DPU-1470, U-2039, U-2040
89407182032-11-16DS, DPU-1470, U-2039, U-2040
86180762030-12-11DS, DPU-1470, U-2039, U-2040
92843422030-09-13DS, DPU-1470, U-2039, U-2040
79645802029-03-26DS, DPU-1470, U-2039, U-2040
86333092029-03-26DS, DPU-1470, U-2039, U-2040
88891592029-03-26DPU-1470, U-2039, U-2040
83342702028-03-21DS, DPU-1470, U-2039, U-2040
85807652028-03-21DS, DPU-1470, U-2039, U-2040
87353722028-03-21U-1470, U-2039, U-2040
90855732028-03-21DS, DPU-1470, U-2039, U-2040
ATC Codes
J: Antiinfectives for systemic use
— J05: Antivirals for systemic use
— J05A: Direct acting antivirals
— J05AP: Antivirals for treatment of hcv infections
— J05AP55: Sofosbuvir and velpatasvir
— J05AP56: Sofosbuvir, velpatasvir and voxilaprevir
HCPCS
No data
Clinical
Clinical Trials
125 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hepatitis cD006526—B19.21325232625109
HepatitisD006505—K75.991313121358
Hepatitis aD006506EFO_0007305B15787101243
Chronic hepatitis cD019698EFO_0004220B18.2464121238
Hepatitis bD006509——110172434
Virus diseasesD014777—B34125119
Chronic hepatitisD006521—K73.912—137
FibrosisD005355————4217
Hiv infectionsD015658EFO_0000764B20——1416
Opioid-related disordersD009293EFO_0005611F11———4—4
Show 22 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
InfectionsD007239EFO_0000544—1813—123
Communicable diseasesD003141——1810—120
Kidney transplantationD016030——121——3
CryoglobulinemiaD003449EFO_0005846D89.1—11——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Chronic kidney failureD007676EFO_0003884N18.6—2———2
Lung diseasesD008171EFO_0003818J98.411———1
Liver transplantationD016031EFO_0010682——1———1
Heart failureD006333EFO_0003144I50—1———1
Heart transplantationD016027EFO_0010673——1———1
LymphomaD008223—C85.9—1———1
B-cell lymphomaD016393———1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Deglutition disordersD003680—R13.11————1
HepacivirusD016174——1————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Recreational drug useD000084783——————22
Healthy volunteers/patients———————11
Kidney diseasesD007674EFO_0003086N08————11
Retinal diseasesD012164—H35.9————11
Gastrointestinal diseasesD005767——————11
Rna virus infectionsD012327——————11
Digestive system diseasesD004066EFO_0000405K92.9————11
Viral hepatitis humanD006525EFO_0004196—————11
Pregnancy complicationsD011248——————11
Patient complianceD010349——————11
Show 2 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameVelpatasvir
INNvelpatasvir
Description
Velpatasvir is a complex organic heteropentacyclic compound that is a hepatitis C virus nonstructural protein 5A inhibitor used in combination with sofosbuvir (under the brand name Epclusa) for treatment of patients with chronic hepatitis C of all six major genotypes. It has a role as an antiviral drug and a hepatitis C virus nonstructural protein 5A inhibitor. It is an organic heteropentacyclic compound, a N-acylpyrrolidine, a L-valine derivative, a carbamate ester, a member of imidazoles, a ring assembly and an ether.
Classification
Small molecule
Drug classantivirals: nonstructural protein 5A (NS5A) inhibitors
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
COC[C@H]1C[C@@H](c2nc(-c3ccc4c(c3)COc3cc5c(ccc6nc([C@@H]7CC[C@H](C)N7C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]c65)cc3-4)c[nH]2)N(C(=O)[C@H](NC(=O)OC)c2ccccc2)C1
Identifiers
PDB—
CAS-ID1377049-84-7
RxCUI—
ChEMBL IDCHEMBL3545062
ChEBI ID—
PubChem CID67683363
DrugBankDB11613
UNII IDKCU0C7RS7Z (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Epclusa – Gilead Sciences
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Vosevi – Gilead Sciences
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 3,167 documents
View more details
Safety
Black-box Warning
Black-box warning for: Epclusa, Epclusa access, Sofosbuvir and velpatasvir, Vosevi
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
19,176 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use